Download
00262_2024_Article_3859.pdf 1,41MB
WeightNameValue
1000 Titel
  • CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients
1000 Autor/in
  1. Strobel, Sophia B. |
  2. Machiraju, Devayani |
  3. Wiecken, Melanie |
  4. Richter, Jasmin |
  5. Klein, Julian A. F. |
  6. Berger, Annemarie |
  7. Hassel, Jessica C. |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2025
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2025-01-03
1000 Erschienen in
1000 Quellenangabe
  • 74(2):59
1000 Copyrightjahr
  • 2025
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00262-024-03859-3 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699187/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title> <jats:p>Cytomegalovirus (CMV) infection or reactivation in immune-compromised individuals can lead to a wide range of severe complications including hepatitis. However, its relation with immune checkpoint inhibitors (ICIs) induced hepatitis (ICI-hepatitis) and tumor responses in advanced melanoma patients remains unclear. Hundred and ninety metastatic cutaneous melanoma patients (mCM) who received ICI treatment, with CMV IgG or IgM information available at baseline, were included in the study (Cohort 1). Clinical characteristics and immune cell count in the blood were retrieved from medical records. In addition, anti-CMV IgG and IgM were measured in pre and on-treatment serum samples from 49 advanced skin cancer patients using ELISA (Cohort 2). In the event of a positive anti-CMV IgM, further analysis with PCR was performed. Univariate and multivariate analysis was used to assess the relationship between CMV IgG or IgM and ICI-hepatitis tumor outcomes. Twenty-one patients (11%) developed hepatitis during ICI treatment (Cohort 1). ICI-hepatitis was significantly associated with disease control rate (DCR; <jats:italic>p</jats:italic> = 0.017) and longer progression-free survival (PFS; <jats:italic>p</jats:italic> = 0.008) in mCM patients. Detection of CMV IgG or IgM antibodies were not associated with ICI-hepatitis (<jats:italic>p</jats:italic> &gt; 0.05). However, increased CMV IgG values at baseline correlated with disease progression (<jats:italic>p</jats:italic> = 0.047) and shorter PFS (<jats:italic>p</jats:italic> = 0.081). In addition, increased CMV IgG values were associated with reduced levels of monocytes (<jats:italic>p</jats:italic> = 0.005), eosinophils (<jats:italic>p</jats:italic> = 0.062), and neutrophils (<jats:italic>p</jats:italic> = 0.065) in the blood. In summary, anti-CMV IgG or IgM in the blood may not be associated with ICI-hepatitis, but high anti-CMV IgG at baseline indicates poor outcomes in ICI-treated mCM patients.</jats:p>
1000 Sacherschließung
lokal IgG
lokal IgM
lokal Antibodies, Viral/immunology [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Melanoma
lokal Aged [MeSH]
lokal Skin Neoplasms/blood [MeSH]
lokal Skin Neoplasms/drug therapy [MeSH]
lokal Immunotherapy/methods [MeSH]
lokal Survival
lokal Male [MeSH]
lokal Hepatitis/immunology [MeSH]
lokal Immune Checkpoint Inhibitors/adverse effects [MeSH]
lokal CMV
lokal Cytomegalovirus/immunology [MeSH]
lokal Peripheral Immune cells
lokal Skin Neoplasms/immunology [MeSH]
lokal Melanoma/drug therapy [MeSH]
lokal Antibodies, Viral/blood [MeSH]
lokal Female [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Cytomegalovirus Infections/immunology [MeSH]
lokal Melanoma/blood [MeSH]
lokal Middle Aged [MeSH]
lokal Immune Checkpoint Inhibitors/therapeutic use [MeSH]
lokal Melanoma/immunology [MeSH]
lokal Hepatitis
lokal Research
lokal Immunotherapy
lokal Prognosis [MeSH]
lokal Hepatitis/etiology [MeSH]
lokal Immunoglobulin G/blood [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U3Ryb2JlbCwgU29waGlhIEIu|https://frl.publisso.de/adhoc/uri/TWFjaGlyYWp1LCBEZXZheWFuaQ==|https://frl.publisso.de/adhoc/uri/V2llY2tlbiwgTWVsYW5pZQ==|https://frl.publisso.de/adhoc/uri/UmljaHRlciwgSmFzbWlu|https://frl.publisso.de/adhoc/uri/S2xlaW4sIEp1bGlhbiBBLiBGLg==|https://frl.publisso.de/adhoc/uri/QmVyZ2VyLCBBbm5lbWFyaWU=|https://frl.publisso.de/adhoc/uri/SGFzc2VsLCBKZXNzaWNhIEMu
1000 Hinweis
  • DeepGreen-ID: 94b4dbd51b48442eaeb7b89ffd5f55db ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Medizinische Fakultät Heidelberg der Universität Heidelberg |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Medizinische Fakultät Heidelberg der Universität Heidelberg |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6507066.rdf
1000 Erstellt am 2025-02-06T13:12:53.631+0100
1000 Erstellt von 322
1000 beschreibt frl:6507066
1000 Zuletzt bearbeitet 2025-09-12T14:28:24.962+0200
1000 Objekt bearb. Fri Sep 12 14:28:24 CEST 2025
1000 Vgl. frl:6507066
1000 Oai Id
  1. oai:frl.publisso.de:frl:6507066 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source